Catalent began supplying Abilify OD Tablets (orally disintegrating) to Otsuka Pharmaceutical Co., Ltd., using its Zydis fast dissolve drug delivery technology. Otsuka’s Abilify OD is for the treatment of schizophrenia and improvement of manic symptoms associated with bipolar disorder. Catalent plans to further invest in its Zydis ODT operations in Swindon, UK to support the increasing demand from the Japanese market.   Dr. Ian Muir, president of Catalent’s Modified Release Technology business sa...